NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free RIGL Stock Alerts $1.34 -0.02 (-1.47%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.3650-Day Range$1.12▼$1.5752-Week Range$0.71▼$1.96Volume636,871 shsAverage Volume1.56 million shsMarket Capitalization$235.01 millionP/E RatioN/ADividend YieldN/APrice Target$5.05 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Rigel Pharmaceuticals alerts: Email Address Rigel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside276.9% Upside$5.05 Price TargetShort InterestHealthy2.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.06) to $0.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector526th out of 947 stocksPharmaceutical Preparations Industry244th out of 432 stocks 3.2 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.05, Rigel Pharmaceuticals has a forecasted upside of 276.9% from its current price of $1.34.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.13% of the outstanding shares of Rigel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 6.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RIGL. Previous Next 3.7 News and Social Media Coverage News SentimentRigel Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Rigel Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows4 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions63.45% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.06) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -8.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -8.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More RIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RIGL Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to "Hold"March 16, 2024 | finance.yahoo.comRIGL Apr 2024 3.000 callMarch 19, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 12, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 12, 2024 | markets.businessinsider.comRigel Pharma Names Rojkjaer EVP, Chief Medical OfficerMarch 12, 2024 | prnewswire.comRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 12, 2024 | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) Upgraded to "Buy" at StockNews.comMarch 11, 2024 | americanbankingnews.comFY2024 EPS Estimates for Rigel Pharmaceuticals, Inc. Boosted by Cantor Fitzgerald (NASDAQ:RIGL)March 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …March 11, 2024 | americanbankingnews.comFY2024 Earnings Forecast for Rigel Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:RIGL)March 9, 2024 | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) PT Raised to $4.00March 9, 2024 | americanbankingnews.comBrokerages Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Price Target at $5.31March 9, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Rigel Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:RIGL)March 9, 2024 | americanbankingnews.comB. Riley Weighs in on Rigel Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:RIGL)March 7, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the YearMarch 7, 2024 | insidermonkey.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | barrons.comRigel Pharmaceuticals Inc.March 6, 2024 | stockhouse.comRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comRigel Pharmaceuticals: Q4 Earnings InsightsMarch 6, 2024 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q4 Earnings SummaryMarch 6, 2024 | msn.comRigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39MMarch 6, 2024 | finance.yahoo.comOwning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),March 6, 2024 | finance.yahoo.comQ4 2023 Rigel Pharmaceuticals Inc Earnings CallMarch 6, 2024 | gurufocus.comQ4 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMarch 5, 2024 | investorplace.comRIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023February 27, 2024 | prnewswire.comRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business UpdateFebruary 26, 2024 | seekingalpha.comRigel Pharmaceuticals: Gavreto Deal Expands Growth ProspectsSee More Headlines Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today3/18/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CUSIP76655960 CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees147Year Founded1996Price Target and Rating Average Stock Price Target$5.05 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+276.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,090,000.00 Net Margins-21.47% Pretax Margin-21.47% Return on EquityN/A Return on Assets-21.21% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.76 Sales & Book Value Annual Sales$116.88 million Price / Sales2.01 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-8.38Miscellaneous Outstanding Shares175,380,000Free Float160,646,000Market Cap$235.01 million OptionableOptionable Beta0.96 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Raul R. Rodriguez (Age 63)President, CEO & Director Comp: $1.09MMr. Dean L. Schorno CPA (Age 61)Executive VP & CFO Comp: $696.67kMr. Raymond J. Furey J.D. (Age 56)Executive VP, General Counsel & Corporate Secretary Comp: $593.46kMr. David A. Santos (Age 61)Executive VP & Chief Commercial Officer Comp: $681.63kMr. Joseph Lasaga (Age 49)Executive Vice President of Corporate Development Ms. Julie PatelSenior VP of Human ResourcesDr. Esteban S. Masuda (Age 62)Executive Vice President of Research Comp: $537.21kMr. Tarek SallamVice President of MarketingMore ExecutivesKey CompetitorsVerastemNASDAQ:VSTMXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAMerrimack PharmaceuticalsNASDAQ:MACKG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 85,467 shares on 3/11/2024Ownership: 5.105%Goldman Sachs Group Inc.Sold 73,480 shares on 3/1/2024Ownership: 0.293%GSA Capital Partners LLPBought 455,601 shares on 2/16/2024Ownership: 0.818%Weiss Multi Strategy Advisers LLCSold 17,873 shares on 2/15/2024Ownership: 0.058%Citadel Advisors LLCSold 4,200 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions RIGL Stock Analysis - Frequently Asked Questions Should I buy or sell Rigel Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares. View RIGL analyst ratings or view top-rated stocks. What is Rigel Pharmaceuticals' stock price target for 2024? 5 brokers have issued twelve-month price targets for Rigel Pharmaceuticals' stock. Their RIGL share price targets range from $1.25 to $15.00. On average, they predict the company's share price to reach $5.05 in the next year. This suggests a possible upside of 276.9% from the stock's current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts. How have RIGL shares performed in 2024? Rigel Pharmaceuticals' stock was trading at $1.45 at the start of the year. Since then, RIGL shares have decreased by 7.6% and is now trading at $1.34. View the best growth stocks for 2024 here. When is Rigel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RIGL earnings forecast. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.04. The biotechnology company earned $28.13 million during the quarter, compared to the consensus estimate of $27.83 million. During the same period in the previous year, the firm posted ($0.11) EPS. What guidance has Rigel Pharmaceuticals issued on next quarter's earnings? Rigel Pharmaceuticals issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $35.7 million-$35.7 million, compared to the consensus revenue estimate of $29.8 million. What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO? 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.81%), Vanguard Group Inc. (5.13%), Vanguard Group Inc. (5.11%), Voya Investment Management LLC (1.20%), Assenagon Asset Management S.A. (1.14%) and Northern Trust Corp (0.88%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RIGL) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.